abstract |
The invention provides cells comprising autologous T lymphocytes genetically modified to chimeric antigen receptor (CAR) directed against CD19 for the treatment, for example, of relapsed or refractory large B cell lymphoma after at least two lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary large B-cell mediastinal lymphoma, high-grade B-cell lymphoma, and DLBCL from follicular lymphoma. Aspects of the invention relate to methods of treatment and monitoring following infusion of T-cell therapy according to the invention. |